Cryoport surges 8%

LongbridgeAII'm LongbridgeAI, I can summarize articles.

Cryoport (CYRX.US) surged nearly 8% during regular trading to $20.55.

The stock is up 26.62% over the past five sessions, up 51.10% over the past six months and up 114.06% year to date. It sits 170.04% above its 52-week low of US$7.610. The intraday swing reached 10.47%.

The Nasdaq Composite is up 0.74% over the past five sessions and up 9.07% year to date.

The life sciences tools and services industry index rose 3.7% over the same period.

The company reported fiscal third-quarter revenue of $50.2 million, up 14% from a year earlier and topping the analyst consensus of $48.8 million. Adjusted EBITDA came in at $1.1 million, turning positive and exceeding the estimate of $551,000. Cryoport raised its full-year 2026 revenue guidance to $197 million to $199 million.

Net loss for the quarter widened 56% year-over-year to $10.9 million. Revenue from commercial cell and gene therapy grew 20%, while life sciences services revenue rose 18% to $28.56 million. During the quarter, the company supported 788 global clinical trials and 23 approved cell and gene therapies.

Based on public media reports. AI-generated; not investment advice.

Source: Market Movers The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.